Rising Incidence of Chronic Wounds & Growing Emphasis on Wound Management to Drive the Global Wound Debridement Products Market

The global market for Wound Debridement Products is projected to reach US$2.5 billion by 2024, driven by rising incidence of chronic wounds, growing emphasis on wound management, and launch of advanced products.

The market for wound debridement products is currently witnessing steady growth driven by a host of factors, such as expanding base of aging population and increasing prevalence of chronic diseases, such as diabetes and obesity; growing incidence of chronic wounds such as diabetic foot ulcers, venous ulcers, pressure ulcers; increasing emphasis on wound management both in developed as well as developing countries; rising need to reduce patient hospital stays; and growing acceptance of wound bed preparation techniques, among others. With debridement constituting a critical element of wound bed preparation, research is constantly underway to develop methods that are highly efficient, less painful and less time consuming and cost effective than existing methods.

Diabetic Foot ulcer is one of the growing areas of focus for wound care companies. Delay in optimal intervention often results in rapid deterioration of the wound, leading to amputation of the affected limb. Diabetic foot ulcers are also major cause of morbidity and mortality as they often lead to serious complications such as infection and amputation, thereby affecting the patient’s quality of life. Wound debridement aims at the management of diabetic foot ulcers and its complications. Besides traditional methods such as surgical debriding and maggot therapy, low frequency direct contact ultrasonic debridement is also employed to manage diabetic foot ulcers. Enzymatic debridement is another method gaining interest to manage DFUs. Among products developed for enzymatic debridement, Smith and Nephew’s Santyl leads the market. Another newer eschar removal product EscharEx® by MediWound Ltd. is undergoing trials. Once approved, EscharEx is believed to take over the shares of Santyl, boding well for the overall market for DFU and VLU therapies, pressure sores, and also for post-trauma and post-surgical wounds.

As stated by the new market research report on Wound Debridement Products, the United States represents the largest market worldwide. Asia Pacific is forecast to emerge as the fastest growing market with a CAGR of 8.1% over the analysis period, led by factors such as growing aging population, increase in standard of living, and growing incidence of diabetic foot ulcers in various countries, such as India and China. Further, with expanding aging population and growing incidence of obesity, the demand is expected to reach new heights in these regions through the forthcoming years. Improved healthcare delivery systems, along with growing participation of the government to streamline healthcare expenditures, also presents favorable growth opportunities for the market.

Major players in the market include Advanced Medical Solutions Group Plc., Coloplast, DeRoyal Industries Inc., Derma Sciences Inc., Lohmann & Rauscher GmbH & Co. KG, Misonix Inc., MediWound Ltd.,  Medline Industries Inc., Smith & Nephew Plc., Soering GmbH, Welcare Industries SpA, and Zimmer Biomet Holdings Inc., among others.

The research report titled “Wound Debridement Products - Market Analysis, Trends, and Forecasts” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, mergers, acquisitions and other strategic industry activities of major companies worldwide. The report provides market estimates and projections in US dollars for all major geographic markets including the United States, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.

For enquiries e-mail us at rsd@strategyr.com or info411@strategyr.com.

For cutting edge analyst reviews on top industries, follow us on Twitter and connect with us on LinkedIn